Introduction

In general, over the years there have been extensive research efforts to develop vaccines for both the opportunistic and endemic fungal infections of man and animals. Several comprehensive reviews and commentaries are available (Deepe, 1997; Perruccio et al., 2004; Feldmesser, 2005; Cutler et al., 2007; Cassone, 2008; Ito et al., 2009; Fidel & Cutler, 2011; Spellberg, 2011). By far, the majority of the work has focused on a vaccine for human infections caused by Candida species. However, considerable effort has been extended toward development of vaccines for cryptococcosis, coccidioidomycosis, blastomycosis, histoplasmosis, paracoccidioidomycosis, infections caused by Pneumocystis and, more recently, aspergillosis. Despite the extensive investigations of these vaccines, none has yet been approved by the US Food and Drug Administration (FDA) for either active or passive immunization in humans.

Table 1 includes an incomplete listing of various entities explored extensively for development of an active vaccine for haematogenously disseminated and mucosal candidiasis. Not all of these entities and strategies are limited to the cell wall of the organism. Table 2 is an incomplete list of various strategies to enhance the activity of Candida vaccines through various adjuvants and delivery systems. Publications describing these strategies have been, in general, highly positive, and have resulted in substantial protection of mice. There is a remarkable paucity of exploration of these vaccines in any other animal models, due at least in part to a greater abundance of knowledge and reagents available relevant to murine immunology. Mice and humans are undoubtedly substantially different regarding their innate immune response to Candida. For instance, mice are naïve to the organism, while Candida species colonize humans extensively, without causing damage to the host. It may be highly desirable for the preclinical evaluation of fungal vaccines, in general, and specifically for vaccines against Candida species, to be conducted in alternative animal models, other than the murine model. While expensive for screening, non-human primates may be a much more suitable model for late-stage vaccine development, since they are not naïve to the organism, and are generally colonized with it, similar to the colonization of humans.

Notable is that the large body of scientific effort directed towards developing a clinically useful fungal vaccine has not resulted in FDA or other regulatory approval of a single entity thus far, especially with the high level of success found in the preclinical models. This complete absence of approval of a fungal vaccine occurs within the context of an ever increasing frequency of opportunistic fungal infections in susceptible patients, especially related to healthcare-associated infections. Fungal infections occurring in this setting carry a mortality rate of approximately 40–50%, even in the face of aggressive antifungal drug therapy (Pappas et al., 2003). These healthcare-associated infections are not limited to patients with iatrogenic immunosuppression, organ transplantation or cancer therapy. They also occur in patients who are not treated with immunosuppressive agents, but have been treated with broad-spectrum antibiotics, indwelling intravenous and intra-arterial lines, prosthetic material implants and hyperalimentation fluids, and in patients who are postoperative or are in intensive care units for other reasons. Burn patients and low birth weight neonates are additional populations of susceptible patients.

In this author’s opinion, the reason for the lack of clinically available fungal vaccines is the result of a confluence of issues. First, there is a general under-appreciation for the magnitude of fungal infections for both the opportunistic fungi and the endemic fungi. Second, there are formidable obstacles in ‘technical transfer’ of successful preclinical studies within the field of fungal vaccines. These obstacles include inadequate staffing of offices for technical transfer in many universities, the competitiveness of small business innovative research and small business technical transfer grants for technical transfer, the high cost of preparing antigens for use in human studies through meeting standards for good manufacturing process, the high cost of preparing antigens for use in human studies through meeting standards for good manufacturing process, the high cost of preparing antigens for use in human studies through meeting standards for good manufacturing process, and the costs of preparing antigens for use in human studies through meeting standards for good manufacturing process.
testing in humans, approximately 3–4 million dollars (USD) are necessary (personal experience). This is obviously a formidable amount for most academic laboratories to accrue, and, to date, large pharmaceutical companies have not engaged in fungal vaccine development through Phase I trials. However, two biotechnical companies have begun Phase I trials; they will be discussed later.

**Newer innovative strategies**

**Live attenuated Candida strain**

Several highly innovative strategies have been published in recent years and will be selectively highlighted herein. A genetically engineered Candida albicans tet-NRG1 strain has been used as an experimental live attenuated vaccine against haematogenously disseminated candidiasis (Saville et al., 2008). This strain is non-pathogenic in the murine model under certain conditions which can be regulated. NRG1 is a negative regulator of filamentation of Candida. In this engineered strain, the gene is under control of a tetracycline-regulatable promoter. In mice not consuming doxycycline in their drinking water (downregulating NRG1, and allowing germination to occur), resulted in substantial protection from the ‘virulence restored’ strain. By using knockout mice, the mechanism of protection was established as being through a T-cell, rather than a B-cell, or neutrophil enhancing mechanism. These results were the highest level of protection described for an anti-C. albicans vaccine, especially in immunocompromised mice or mice with neutrophil deficiency. This was a highly innovative and effective active vaccine strategy, and may provide valuable background for further development. However, it does require the use of a live, attenuated strain of Candida, which could face formidable challenges regarding safety evaluation by the FDA for approval in humans.

### β-Mannan and peptide conjugates

Another highly innovative approach for Candida has been developed by Xin et al. (2008). These investigators have created a collection of six glycopeptides vaccines by combining β-mannan and peptide epitopes. Five of the resulting glycopeptides induced protection against murine disseminated candidiasis. The six T-cell peptides from *C. albicans* cell wall proteins were selected by algorithm peptide epitope screening. Each of the peptides was then synthesized and conjugated to the fungal cell wall β-mannan trisaccharide [β-(Man)₃] by a novel saccharide–peptide linker to create the glycopeptides conjugates. This linker was a non-immunogenic, cross-coupling reagent, which resulted in a stable amide bond. In the immunization strategies, dendritic cell presentation was used, and complete Freund’s adjuvant was used as an adjuvant. Either strong or moderate protection was seen with five of the six glycopeptides. One of the antigens was associated with an increased mortality in challenged control mice compared to challenged vaccinated mice, thereby being non-protective. Of significant importance is that these protective responses were mediated by fully synthetic, chemically defined, immunogens, and represent an approach that may have widespread implications for the development of vaccine antigens. Recent additional studies (Xin & Cutler, 2011) have shown that a peptide alone (Fba) has been highly protective as an active vaccine against several *C. albicans* strains and that the monoclonal antibody specific for the peptide, E2-9 (IgM), was protective when used in passive transfer. These experiments substantiate the role of antibody in protection in this murine model.

### β-Glucan conjugate vaccine for Candida

Further exploration of vaccine strategies for *Candida* using cell wall antigens has been accomplished by Pietrella et al. (2010). They have used β-glucan conjugated with laminarin-CRM together with the adjuvant MF59. Excellent protection was seen for vaginal candidiasis in their murine model. Their studies were of further value in demonstrating the use of a genetically engineered, luminescent *C. albicans* strain, which allowed *in vivo* evaluation of the vaccine efficacy. The *in vivo* evaluation reflected colony
counting measurements accurately. The adjuvant MF59 has been used extensively in influenza vaccines in Europe, but it is not currently approved by the FDA for use in the US. It has the property of rapid recruitment and activation of helper CD4\(^+\) cells. This response is thought to promote higher titres of antibody response. Passive transfer experiments demonstrated the protection in this model to be mediated by antibody. Additionally, passive vaccination with a \(\beta\)-glucan monoclonal antibody resulted in protection against the vaginal candidiasis as well. Of additional interest is that this monoclonal antibody also recognizes the linear epta- or octa-\(\beta\)-1,3 glucan epitope present in the cell wall proteins Als3p and Hyr1p. These proteins are thought to play roles in hyphal growth, and adherence and invasion of human cells. Because of the combined T helper (Th)1 and B-cell activity of MF59, it may be an attractive vaccine adjuvant for fungal vaccines (Brito et al., 2011).

**Sap2p vaccine for vaginitis caused by Candida species**

This vaccine is based on a recombinant, truncated form of Sap2p. This protein is not actually a cell wall protein, but rather is a secreted aspartyl protease. The role of the SAP gene family in virulence has been reviewed recently (Correia et al., 2010). The vaccine is targeted to prevent recurrent vulvaginitis. A brief discussion of a clinical trial with this protein is in the later part of this discussion under the human studies section.

**Preclinical studies for the rAls3p-N vaccine**

Our group has been working for years on a cell wall protein based-vaccine strategy, which has been recently tested in humans in a Phase I clinical trial (Hennessey et al., 2011). This work began after we discovered that Als1p is an adhesin enabling *Candida* to bind to human vascular endothelial cells. This discovery was made by transforming the non-adherent *Saccharomyces cerevisiae* with genomic *Candida* DNA fragments and testing for conversion of *Saccharomyces* from non-adherent to adherent. The use of surrogate genetics was successful, and cloning of the gene responsible for this conversion led to the identification of ALS1 as the gene mediating adherence. That discovery occurred shortly after Hoyer et al. (1995) had discovered the ALS genes in their efforts to determine the genetics responsible for the filamentation of *Candida*. Once the adhesive characteristics of Als1p were determined, we performed classic gene disruption studies, as well as over-expression studies, to confirm that the protein was acting as an adhesin in *C. albicans*. Our research focus split at that time into further investigations of the precise mechanism of adherence, and we began studies to determine whether the protein could act as an immunogen. We produced larger quantities of the protein by recombinant technology in *Saccharomyces cerevisiae*. The protein was purified using a nickel column to precipitate a His-tagged protein encoded by the *C. albicans* gene. Initial vaccination studies included the adjuvant complete Freund’s adjuvant inoculated with the recombinant N-terminus of Als1p (rAls1p-N). For nearly all studies, BALB/c mice were inoculated subcutaneously, boosted in 3 weeks, then infected 2 weeks after the booster with lethal doses of *C. albicans*. Initial studies were performed with the common *C. albicans* strain SC5314. Characteristically, 40–60% of vaccinated mice survived a 30 day observation time compared to 100% lethality in 10–14 days in mice receiving adjuvant control. Similar encouraging results were seen in severely neutropenic mice, steroid-treated mice, and in murine models of oropharyngeal candidiasis and *Candida* vaginitis. These studies were advanced into a trial in non-human primates to determine the extent of IgG response when rAls1p-N was given with aluminium hydroxide as the adjuvant. IgG titres rose by 1–2 logs in these primates, which, unlike mice, are not naïve to *Candida*.

Since Phan et al. (2007) showed that Als3p was not only an adhesin, but also an invasin for *Candida* in endothelial cells, rAls3p-N was tested as a vaccine and was shown to be approximately equal in efficacy to rAls1p-N. Because of this dual property of Als3p, our studies were continued using it as the primary antigen. The combination of rAls1p-N and rAls3p-N did not show increased efficacy over either antigen alone.

Adoptive transfer experiments using B-cell and T-cell knockout mice were used to explore the mechanism of the vaccine protection. B-cell knockout mice transfused with B-cell lymphocytes harvested from mice, which had been vaccinated with both rAls1p-N and rAls3p-N, did not show protection when challenged with *C. albicans*. Also, serum from mice vaccinated with rAls3p-N was not protective in the lethal challenge model. Furthermore, IFN-\(\gamma\)-deficient mice were not protected by the vaccine. However, in T-cell knockout mice which were transfused with T cells harvested from vaccinated mice, protection against the lethal challenge was observed, demonstrating that the major mechanism of protection was due primarily to T cells and not due to B cells or antibody production by the vaccine (Ibrahim et al., 2005). However, antibody production was induced in the mice by the vaccine.

These studies have been extended further to define the mechanism of protection (Lin et al., 2009). In these experiments, neither mice with cyclophosphamide-induced neutropenia nor mice deficient in gp91\(\text{phox}\)–/– (mice which have neutrophils unable to generate superoxide and have neutrophil microbial killing deficiency) were protected by vaccination with rAls3p-N, indicating that functional neutrophils were essential for the vaccine mechanism of protection. Adoptive transfer of CD4\(^+\) positive lymphocytes from vaccinated mice into the gp91\(\text{phox}\)–/– mice also failed to protect, as anticipated.

To determine whether IL-17 was necessary for the vaccine mechanism of action, mice deficient in IL-17A were vaccinated and compared to wild-type vaccinated control mice. No vaccine-induced protection was seen in the IL-17A-deficient mice in comparison to the vaccinated and...
protected control mice, suggesting that, in part, the vaccine required IL-17A. When unvaccinated IL-17A-deficient mice were compared to unvaccinated control mice and challenged with \textit{C. albicans}, no difference was seen, suggesting that IL-17A is not necessary for innate protection, not related to vaccination.

To determine whether CD4\(^+\) cells were the source of the IL-17A, IL-17A-deficient donor CD4\(^+\) cells were transferred to wild-type recipient mice and wild-type CD4\(^+\) donor cells were transferred to IL-17A-deficient recipient mice. The CD4\(^+\) cells from vaccinated wild-type mice resulted in protection of the IL-17A-deficient mice challenged with \textit{C. albicans}. As anticipated, transfer of CD4\(^+\) cells from vaccinated IL-17A-deficient mice did not protect against the \textit{C. albicans} challenge. These experiments are evidence that CD4\(^+\) cells are the source of IL-17A in vaccinated mice.

To define the populations of cells induced by vaccination, spleens and lymph nodes were taken from vaccinated and control non-vaccinated mice 2 weeks after the boost of the vaccinated mice. These cells were stimulated with rAls3p-N, IFN-\(\gamma\) and IL-17, as well as neutrophil activating chemokines KC and MIP-1\(\alpha\), were produced in higher quantity than in the non-vaccinated control mice cells. Supernatants from the vaccinated mice stimulated neutrophils much more extensively than supernatants from the non-vaccinated control mice. Additionally, vaccinated mice had a substantial reduction in kidney fungal burden; myeloperoxidase levels were increased in the kidneys in vaccinated mice, as well as the influx of neutrophils, as quantified on histopathology. Additionally, increased levels of IFN-\(\gamma\), IL-17 and the neutrophil activating cytokine CXC were found in the kidneys.

In vaccinated mice, there were higher levels of Th1, Th17 and Th1/17 cells than in non-vaccinated controls. CD4\(^+\)CCR6\(^+\) cells were enriched in the Th1 cells; CD4\(^+\)CCR6\(^+\) cells were enriched in the Th17 cells. A substantial portion of the spleen and lymph node CD4\(^+\)CCR6\(^+\) cells were Th1/17 cells.

In summary regarding the mechanism of action of the rAls3p-N vaccine in mice, the following points can be made. IFN-\(\gamma\) and IL-17A were necessary for vaccine-induced protection in mice. The source of the IL-17A and IFN-\(\gamma\) was Th1, Th17 and Th1/17 lymphocytes. These cytokines mediated recruitment of neutrophils, due to CXC and MIP-1\(\alpha\), to the site of infection, which resulted in a decreased tissue burden. IL-17A was not necessary for defence against \textit{C. albicans} challenge in non-vaccine immune defence, but was necessary in vaccine-induced protection.

**Protection against \textit{Staphylococcus} by the \textbf{Candida} rAls3p-N vaccine**

In our studies of the molecular mechanism of attachment of \textit{C. albicans} to human cells, we performed molecular modelling of all the Als proteins (Sheppard \textit{et al.}, 2004). Of great interest is that high levels, 80–90\%, of three-dimensional (3D) homology were found between the Als proteins and cell surface molecules on non-fungal organisms, including bacteria and viruses. Of note was the homology found with clumping factor (ClfA), a cell surface molecule of \textit{Staphylococcus aureus}. When identifying this 3D homology, we decided to determine whether rAls3p-N could induce a protective response as a vaccine against \textit{S. aureus}. Mice were immunized with rAls3p-N, according to standard protocols used for the \textit{C. albicans} vaccination, and then challenged with \textit{S. aureus}. Protection results were similar to those for \textit{C. albicans}, demonstrating a ‘cross-kingdom’ protection (Spellberg \textit{et al.}, 2008). Extensive studies of the mechanism of the protection have shown it to be essentially identical to the mechanism for rAls3p-N protection, primarily a T-cell mechanism rather than a B-cell mechanism and not dependent primarily on antibody, as determined by adoptive transfer experiments.

**Current human studies of vaccines against \textbf{Candida} species**

**Human studies of the rAls3p-N \textit{Candida} vaccine**

These studies described above have led to a Phase I clinical trial in human subjects performed by NovaDigm Therapeutics (Hennessey \textit{et al.}, 2011). Subjects (30) were given two doses of vaccine, 30 \(\mu\)g and 300 \(\mu\)g. The vaccine induced no related adverse events and was well tolerated. It should be noted that all the studies of the mechanism of action of the vaccine to date have been done in the murine model and may not translate perfectly to humans. For instance, the Phase I clinical trial in humans showed a robust production of IgG and IgA1 antibodies in the majority of the subjects (Hennessey \textit{et al.}, 2011). Most of the human subjects also had an increase in production of IFN-\(\gamma\) as well as IL-17A, as determined by ELISpot measurement. These observations suggest that in humans, the T cells, B cells and antibodies are all stimulated by the vaccine. We have retained peripheral blood mononuclear cells (PBMCs) and serum from the human subjects in their pre- and post-vaccinated state, and now have the capability of defining, in much more detail, the human vaccine response to this purified fungal antigen. Of great interest will be determining the opsonophagocytic activity of the human serum for both \textit{Candida} and \textit{Staphylococcus}. These studies are currently in progress. Also a detailed study of the T-cell response is planned for the PBMCs. Studying these human pre- and post-vaccine resources should allow a highly enhanced definition of the mechanism of action of the vaccine, as well as possibly defining more useful surrogate markers, or combination of markers, for determining vaccine efficacy in future trials.

If this vaccine proves to be efficacious, it could have utility in a variety of clinical settings including vaginitis caused by \textit{Candida} species, skin and soft tissue infections caused by \textit{S. aureus}, and in patients who acquire either organism in the healthcare-associated setting, particularly in the intensive care unit. In the latter circumstance, the vaccine would be given to selected patients who are in high-risk groups, such
as patients undergoing cardiovascular, thoracic or gastrointestinal surgery. Many of these patients could receive the vaccine preoperatively, even before entry to the intensive care unit. Patients with immunosuppression (iatrogenic, such as those treated with cytotoxic cancer chemotherapy) are far less likely to benefit from an active vaccine, and do not comprise the largest group of patients acquiring bacteremia or other infections caused by these two organisms. Such patients may benefit from a passive vaccine given either alone or in combination with an active vaccine. Obviously, it would be highly desirable for an active vaccine to have a rapid onset of efficacy, when used in this healthcare-associated setting. In that context, the rAls3p-N vaccine elicited high antibody titres within 3–7 days after administration in the completed Phase I clinical trial (Hennessey et al., 2011). Unlike vaccines given to large populations of subjects designed to create ‘herd’ immunity, the duration of efficacy for a vaccine used to prevent or ameliorate healthcare-associated infections would need to be efficacious only during the time the subjects were at risk for infection.

**Human trials of the Sap2p vaccine for vaginitis caused by Candida species**

In 2010, a clinical trial based on a recombinant, truncated form of Sap2p was begun in Europe. The vaccine is targeted to prevent recurrent vulvaginitis. It is being delivered in both intramuscular and intravaginal forms with a proprietary virosome. This active vaccine is being developed by Pevion Biotech, and interim data indicate that it is well tolerated and is ‘effective’ at low doses. A full description of the results of the Phase I trial is not currently in the public domain.

**Vaccine development for other fungal pathogens causing haematogenously disseminated disease**

**Coccidioidomycosis**

Currently, vaccine development for other fungal organisms has not reached clinical trials, with the exception of vaccines for *Coccidioides immitis*. A clinical trial for a vaccine for coccidioidomycosis was performed as long ago as 1975 (Pappagianis & Levine, 1975), and again in 1993 (Pappagianis & The Valley Fever Vaccine Study Group, 1993). However, there has not been further advancement of trials in humans for over 18 years now, and a vaccine for the prevention of coccidioidomycosis has not yet been approved by the FDA. However, extensive preclinical development of a coccidioidomycosis vaccine is still under way (Shubitz et al., 2008; Capilla et al., 2009; Xue et al., 2009). Previous studies have included a variety of strategies. For instance, a recombinant enzyme antigen, a 4-dehydroxyphenylpyruvate dioxygenase, has been shown to be protective in mice against an intraperitoneal challenge with arthroconidia of *Coccidioides* (Wyckoff et al., 1995). Additionally, an extract of the outer cell wall of spherules (SOW) has also conveyed protection in the same mouse model (Wyckoff et al., 1995). Further studies with a water-soluble antigen (C-ASWS) showed partial protection in mice with a natural relative resistance to *Coccidioides immitis* (Kirkland & Fierer, 1985). Additional studies have been performed with a 33 kDa antigen isolated from spherules (Galgiani et al., 1996). This antigen was recognized from sera of patients who had recovered from natural infection. Other more recent studies have included a variety of other antigens and approaches (Kirkland et al., 2006; Tarcha et al., 2006; Awasthi, 2007; Johnson et al., 2007a; b; Lunetta et al., 2007).

Of interest is an important recent study that examined the mechanism of action of a live, attenuated mutant of *Coccidioides posadasii*, used as a vaccine in mice. The attenuated organism has a double gene knockout, *CTS2* and *CTS3*, which are both chitinase genes (Xue et al., 2009). This attenuated mutant is not able to sporulate. Mice are fully protected against pulmonary coccidioidomycosis by this vaccine. Profiles of the cytokines found in lung homogenates of the vaccinated mice, which were challenged with intranasal organisms, showed a mixed Th1-, 2- and 17-type immune response. Functional Th17 cells were necessary for protection by the vaccine in this model, adding to the growing evidence for the role of Th17 cells in the mechanism of protection of most of the fungal vaccines under evaluation (Hung et al., 2011). If this strategy is to move forward into human trials, concerns over the potential for this organism, a eukaryote, to mutate back to a virulent form will require addressing. However, there are several live, attenuated viruses in clinical use today.

**Blastomycosis**

Historically, considerable effort has been made by the group in Wisconsin, led by Bruce Klein, to both elucidate the mechanisms of natural resistance to *Blastomyces dermatitidis*, and to develop a vaccine for blastomycosis. A highly immunogenic cell wall protein, WI-1 (now designated BAD-1), has been the major focus (Klein & Jones, 1994). This antigen stimulates humoral and T-cell immunity as well as serving as a ligand for phagocytes. This antigen has been protective in mice, probably mainly through a Th2-type response. Recently, the group has used the innovative strategy of a live, attenuated vaccine in beagles and foxhounds (Wütrich et al., 2011a). BAD-1 is a cell surface protein, which is an adhesion for *B. dermatitidis* (Brandhorst et al., 1999). Additionally, it has also been shown to be essential for pathogenicity in the mouse model for lethal pulmonary infection. A strain of *B. dermatitidis* has been mutated through knocking out the gene encoding BAD-1 and given live to beagles and foxhounds subcutaneously, without adjuvant. The safety of this vaccine was established; it was also immunogenic. A protection evaluation was not part of this initial experimental design for developing a canine vaccine for blastomycosis.

In this study, lymph nodes were reactive, showing an increase in well-differentiated lymphocytes and follicules, as well as macrophages, and the presence of vaccine organisms. No evidence of dissemination of the attenuated
vaccine organisms was found in the lung samples. In vitro lymphocyte proliferation was induced with a protective cell wall antigen from B. dermatitidis. Increased transcript levels of IFN-γ and TNF-α were found, as well as of GM-CSF, but not of IL-4. The immune responses in this study were vaccine dose-dependent. In general, cellular immunity has been found to be operative in vaccine responses for blastomycosis (Deepe et al., 2005).

Of considerable interest is recent preclinical work on the mechanism of vaccine-induced protection against three systemic mycoses endemic to North America (Coccidioides posadasii, Histoplasma capsulatum and B. dermatitidis) (Wü thrich et al., 2011b). The role of Th17 cells in natural innate immunity for fungal infections has been controversial, and has differed somewhat from fungal organism to fungal organism. In these elegant studies, knockout mice and adoptive transfer technology were used extensively. CD4+ cells from draining nodes produced IL-17 and IFN-γ in response to antigen and were antigen-specific. To determine whether primed IL-17 cells migrated to the lung of vaccinated mice after pulmonary challenge, transcript and the number of cytokine-producing lung lymphocytes were assayed. Th17 cells were necessary and sufficient for protection against these three organisms. Furthermore, protection was dependent upon Myd88, but not Dectin-1. IL-17A, IL-17F, IL-22 and IFN-γ were elevated. Of interest is that these findings differ from those of one report, in which vaccinated mice with Th17 polarization had increased inflammation of both gastric candidiasis and pulmonary aspergillosis (Zelante et al., 2007). However, in the mouse model for haematogenously disseminated candidiasis, Th17 polarization has been essential for vaccine-induced protection (Lin et al., 2009). These studies strongly suggest that human vaccines for systemic fungal infections should be designed to induce Th17 cells as well as antibodies.

**Histoplasmosis**

Historically, efforts have been made to develop a vaccine for the prevention of histoplasmosis. Extracts of the cell wall and cell membrane (CW/M) (Garcia & Howard, 1971), as well as a ribosomal–protein complex, have been evaluated with successful results (Tewari et al., 1978). A protein subfraction of the CW/M preparation, termed HIS-62, was found to be efficacious in three different mouse models (Gomez et al., 1995). HIS-80, another CW/M derivative, has also been protective in mouse models (Gomez et al., 1991). More recently, a heat-shock protein has shown protection in mice (Scheckelhoff & Deepe, 2002). Another innovative approach taken recently is the use of apoptotic neutrophils (Hsieh et al., 2011).

**Aspergillosis**

Attention has also been directed toward vaccine strategies for Aspergillus (Ito et al., 2009). This organism is particularly problematic in haematopoietic cell transplantation (HCT) recipients, who have response rates to conventional therapy of approximately 31% (Herbrecht et al., 2002). L. Romani and the mycology group at the University of Perugia, Italy, over a decade ago, demonstrated that they could protect neutropenic mice with a crude culture filtrate (CCFA) vaccine given intranasally prior to induction of neutropenia. Mice were challenged with intranasal inhalation of Aspergillus spores. Later they also demonstrated that the allergen Asp f 16, when given with oligodeoxynucleotide adjuvants, was also protective (Bozza et al., 2002). They have also shown that dendritic cells pulsed with Aspergillus conidia, or transfected with conidial RNA, were protective for mice undergoing HCT (Bozza et al., 2003).

Additionally, dendritic cells transduced with an adenoviral vector encoding production of IL-12 and pulsed with Aspergillus has been effective in mice (Shao et al., 2005). Furthermore, a glucan from Laminaria digitata conjugated with the diphtheria toxoid CRM197 has been effective for protecting against an intravenous challenge with Aspergillus in mice (Torosantucci et al., 2005).

J. Ito and the group at City of Hope have attempted vaccination in mice with freeze–thawed hyphae and culture supernatants of Aspergillus. After efficacy was established, they identified the allergen Asp f 3 as the likely immunogen (Ito et al., 2009). After synthesizing recombinant Asp f 3, they were able to establish protection in mice with the protein in combination with the adjuvant TiterMax. Since Asp f 3 is an allergen, and to avoid the possibility of inducing an allergic response, truncated forms of the protein were used, which were also protective in steroid-suppressed mice. They have further defined the protective epitopes of the truncated proteins that were responsible for T-cell Asp f 3 specific stimulation (Ito et al., 2009).

**Pneumocystis, paracoccidioidomycosis and cryptococcosis**

A historical review of vaccine development for pneumocystis, paracoccidioidomycosis and cryptococcosis is beyond the scope of this update. Extensive efforts have been made for all three diseases. Encouraging results have been seen recently with a DNA vaccine strategy for pneumocystis (Feng et al., 2011) and paracoccidioidomycosis (Fernandes et al., 2011). A recent study has been published regarding active vaccination for cryptococcosis (Chow & Casadevall, 2011). In this study, a galactoxylomannan–protein conjugate was used in mice. Although it did stimulate antibody production, it failed to result in protection of vaccinated mice compared to controls.

**Recent innovative studies with Saccharomyces**

Of further interest is the work performed by the group at the Santa Clara Valley Medical Center affiliated with Stanford University, led by David Stevens. It represents a return to earlier studies inducing immunity in mice to Candida by vaccination with heat-killed organisms. The group has shown protection in mice by vaccination with
heat-killed *Saccharomyces cerevisiae* against Aspergillus, *Coccidioides*, Cryptococcus and Candida (Capilla *et al.*, 2009; Liu *et al.*, 2011a, b; Stevens *et al.*, 2011). The killed *Saccharomyces* induced a specific and comprehensive immune response; both Th1 and Th2. CD4+ and CD8+ cells were stimulated as well as antibody against *Saccharomyces* glucan and mannan. IFN-γ, IL-6 and IL-17A cytokine production was stimulated also. Alum enhanced the vaccine effect. The constituents in the heat-killed preparation inducing the protective response are not currently known. The IL-17A production is consistent with the growing body of literature verifying that the Th17 pathway is important, not only for innate protection against most fungal organisms, but also for efficacious vaccine responses.

**Summary**

In summary, for decades a variety of cell wall antigens (and non-cell wall antigens) from both the opportunistic and the indigenous fungi have been evaluated in preclinical studies. Nearly all of this work has been done in mouse models of vaccination followed by challenge of the fungal organism. There is an extreme paucity of data in humans, due to the small number of clinical trials which have been done to date.

With the exception of the early trials with preparations from *Coccidioides immitis*, at a time when only limited data were derived from the blood of subjects, none of the preclinical work has translated into human trials until recently, when two Phase I trials in human subjects started. Both trials are limited to strategies for prevention of candidiasis. A major reason for the lack of human trials for fungal vaccines has been the very high costs related to good manufacturing process production of the antigens, toxicity studies in animals, and high costs for clinical trials in humans. At present, approximately 3–4 million dollars (USD) are necessary for these steps to be completed. This sum does not include the cost of any clinical trials beyond Phase I. Of encouragement is the growing interest in the private sector of participating in the development of fungal vaccines, especially to address the ever growing problem of healthcare-associated infections. It is likely that in most countries these large costs will be covered by either private funding sources or a combination of private and governmental funds, rather than governmental funds alone.

As data emerge from these early clinical studies, the usefulness of the mouse model for the preclinical development of fungal vaccines will become substantially more clear. However, it is highly likely that the mouse model will have limited utility in accurately predicting vaccine efficacy in humans. If that situation is established, other models will be explored for their utility in preclinical exploration for vaccine strategies not only to prevent fungal infections but to have the added advantage of slowing resistance development to the currently highly limited fungal armamentarium.

**Acknowledgements**

Dr Edwards is a recipient of NIH grants AI063382, AI1990 and R41 AI071554. He is also a recipient of a Bristol Meyer Squibb Freedom to Discover Award for Infectious Diseases. Additionally, he thanks the US Military for support of development of the rAls3p-N vaccine, the Los Angeles Biomedical Institute at Harbor/UCLA Medical Center, and NovaDigm Therapeutics, Inc. Dr Edwards is a co-founder and equity holder of NovaDigm Therapeutics. The following individuals have played key roles in the preclinical and clinical development of the rAls3p-N vaccine: Ashraf Ibrahim, Michael Yeaman, Yu Fue, Scott Filler, Brad Spellberg, Don Sheppard, John Hennessey, Clint Schmidt, Beth Ann Zupi, Mary Myfield, Adam Scheidegger, Jo White, Will Josephs, Tuomas Holmberg and Tim Cooke.

**References**


Vaccination with apoptotic phagocytes

Immunization with apoptotic phagocytes


